Alzheimer disease trials in China

In China 134 Also abroad 816

134 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Acoustic Stimulation During Sleep for Alzheimer's Disease
Where
Beijing
Age
60 years to 75 years
People
40
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT07924657
No phaseNot yet taking people in China
40 Hz Audio-Visual Stimulation Therapy for AD
Where
Xiamen
Age
50 years to 80 years
People
50
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07926438
Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Haidian District, Hangzhou, Kunming, Nanjing, Shanghai, Shenzhen, Tianjin, Xian
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
No phaseTaking people
Community-based Screening for Alzheimer's Disease
Where
Shanghai
Age
60 years to 80 years
People
3,000
Run by
Kuang XiaoJun
See details and how to joinNCT07570719
Phase 2Taking people
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Where
Beijing
Age
55 years to 85 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07688213 · EU 2025-524581-14-00
Phase 3Taking people
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Where
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Xi'an, Xianyang
Age
55 years to 80 years
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07717411
No phaseTaking people
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Where
Shanghai
Age
18 years and over
People
3,000
Run by
Fudan University
See details and how to joinNCT07923812
Phase 1Taking people
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
Where
Beijing, Minhang District, Shanghai
Age
18 years to 85 years
People
179 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07787169
No phaseNot yet taking people in China
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Where
Hong Kong
Age
40 years and over
People
1,600
Run by
Chinese University of Hong Kong
See details and how to joinNCT07917182
No phaseTaking people
Network-Guided Individualized TMS for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
Where
Hefei
Age
50 years to 90 years
People
40
Run by
Anhui Medical University
See details and how to joinNCT07692542
No phaseTaking people
China HEalthy Aging and Dementia Study (HEAD)
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Qingdao, Shanghai, Shenzhen, Taizhou, Tianjin, Wuhan, Xiamen, Xining, Zhoukou
Age
18 years and over
People
20,000
Run by
Fudan University
See details and how to joinNCT07912710
Phase 2Not yet taking people in China
A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
Where
Beijing
Age
55 years to 90 years
People
200
Run by
Vigonvita Life Sciences
See details and how to joinNCT07905352
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanjing, Ningbo, Shanghai, Shenzhen, Tianjin, Xi'an, Zhenjiang
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
No phaseTaking people
Fuzhou Aging Brain Health Initiative
Where
Fushun, Fuzhou
Age
55 years to 90 years
People
3,000
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT07891429
Phase 1Taking people
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
Where
Beijing, Minhang District, Shanghai
Age
18 years to 85 years
People
68 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07787182 · EU 2026-527295-81-00
No phaseEnrolling by invitation
Brain Heath Service for Prevention of AD
Where
Hong Kong
Age
55 years to 80 years
People
4,000
Run by
Chinese University of Hong Kong
See details and how to joinNCT07834528
Phase 3Taking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing, Shanghai, Suzhou, Xuzhou
Age
50 years to 90 years
People
80,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Tianjin, Wenzhou, Xi'an, Zhenjiang
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Where
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenzhen, Tianjin, Wenzhou, Zigong
Age
55 years to 90 years
People
500 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Beijing, Changsha, Guangzhou, Haidian District, Hangzhou, Kunming, Nanjing, Shenzhen, Tianjin
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
No phaseTaking people
Study on Clinical Characteristics of Patients With Probable Alzheimer's Dementia Stratified by Blood Biomarkers
Where
Tianjin
Age
55 years to 90 years
People
200
Run by
Tianjin Anding Hospital
See details and how to joinNCT07875998
No phaseTaking people
A Prospective Cohort Study of Multimodal Biomarkers and Progression From Mild Cognitive Impairment to Dementia
Where
Beijing
Age
50 years and over
People
600
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT07876570
Phase 1Not yet taking people in China
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Where
Beijing, Minhang District, Shanghai
Age
18 years to 85 years
People
111 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07843459
Phase 2Taking people
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Where
Beijing, Hangzhou, Hefei, Nanjing, Shanghai Shi, Wuhan
Age
55 years to 90 years
People
120 worldwide
Run by
Celgene
See details and how to joinNCT06808984
Phase 2Taking people
To Evaluate the Safety and Efficacy of RP902 Tablets
Where
Beijing
Age
50 years to 85 years
People
360
Run by
Risen (Suzhou) Pharma Tech Co., Ltd.
See details and how to joinNCT07579884